United States Next Generation Sequencing Market Report by Products, Application, Technology, End-Users, and Company Analysis 2024-2032

United States Next Generation Sequencing Market Size

United States next-generation sequencing (NGS) market is set to expand from US $3.16 billion in 2023 up from US$13.75 billion by 2032, with the compound annual growth rate of 17.75 percent from 2024 to 2032. This market growth is driven by improvements in genomics technology; the trend towards the increased adoption of biotechnology and pharmacogenomics; augmented research and development expenditure in biotechnology and healthcare industries.

United States Next Generation Sequencing Market Outlooks

Next generation sequencing (NGS) is a breakthrough genome sequencing platform that can sequence huge amounts of DNA in a short period of time. Compared with conventional methods, NGS can process millions of fragments in a single run and thus more efficient and economical. This technology has revolutionized genomics since it makes it possible to accomplish mapping of the whole genome, thus making it easier for scientist to discover genetic factors that are accountable for causing diseases, study complexity heritability's as well as dissect diverse mechanisms of biological procedures.

In the United States, New Generation Sequencing, or NGS has a wide range of uses within different sectors that comprises medicine, agriculture, and environment. In healthcare, it is used to address the challenges that are associated with phenotypic individuality; it identifies specific mutation that determines the best treatment plan for cancer patients. Furthermore, they use NGS for prenatal diagnostics to identify inherited disorders, and for studying evolution of pathogens in the context of epidemiological investigations. In agriculture the use of NGS has been used in crop breeding where genetic data is used to enhance the resilience and productivity, in environment science, NGS is used in bio dispersion and ecosystem surveys.

Moreover, increase in the occurrence of cancer in U.S. is projected to drive the NGS market. According to American Cancer Society, there will be about 2,001,140 new cases of cancer and 611,720 cancer deaths in the United States of America in 2024. Oncology is one of the major areas of application of NGS besides tumor profiling and identification of genetic mutations that can help in predicting treatment outcomes. Cancer genomics, understanding of tumors molecular characteristics as well as the progress in the field of targeted treatments are one of the leading NGS market drivers.

Growth Driver of the USA Next Generation Sequencing Market

Increasing Demand for Personalized Medicine

Increase in the prevalence of targeted therapy is an underlying growth factor for the Next Generation Sequencing (NGS) market in the United States. In the current healthcare, patients are now being treated basing on their genotyping or phenotyping, therefore NGS is important in analyzing several mutations or variations. It also allows the health care personnel to choose a specific treatment, which in turn leads to better success rates and fewer side effects. Due to more and more patients' and doctors' recognition of genetic testing, there are greater numbers of investments in NGS, technology, and services.

Advancements in NGS Technology

The multitudinous evolution of NGS equipment and its constant improvement are contributing to the exponential growth of the market. Advancements like higher accuracy of the sequence, faster NGS, and decrease cost makes it highly relevant for the applications in research as well as diagnostic areas. Modern bioinformatics tools and software have also developed more advanced, which help in deciphering the complicated genomic data. Technological advancements of these technologies get more users and increase the areas of application of NGS, hence more adoption in diverse fields. The acquisition of Verogen, a company which applies NGS technologies for human identification and forensic investigation was confirmed in January 2023 by QIAGEN. The acquisition of Verogen's NGS tools, and professional services helps the company diversify its product offering.

Growing Applications in Research and Clinical Diagnostics

The dynamics of technology advancement in the field of NGS in research, diagnostics, and therapeutics are essential for growth in the market. For instance, it is widely used in genomics, transcriptomics, and epigenomics in academic and pharmaceutical research to facilitate discoveries of the diseases. In clinical context NGS improves the diagnostic yield especially in oncology and genetic disorders. Because of the NGS-based tests gaining regulatory approval, facility use of these technologies is more likely to integrate into daily practice, thus advancing the market and the care of patients. Another interesting fact about the NGS market is that various government programmes in the United States have sponsored its funding immensely. The CDC provides financing for a large number of public health-related projects, including those aimed at programs on genomic surveillance. In September 2022, The American Rescue Plan funded USD 1.7 billion to support the genomic surveillance strategies that shall be implemented across the country. From this funding, there will be a part dedicated to innovation while USD 90 million will be set to support the sustenance of Pathogen Genomics Centers of Excellence network for the coming five years. A CDC funding is used in order to promote NGS implementation in public health laboratories in order to increase their ability for the identification, characterization, and response to pathogens.

United States Next Generation Sequencing Company Analysis

The top companies in the United States Next-Generation Sequencing Market are Illumina, Thermo Fisher Scientific, Pacific Biosciences, QIAGEN N.V, Roche, Bio-Rad Laboratories, Inc., Takara Bio Inc., Hamilton Company, and BioMerieux SA.

United States Next Generation Sequencing Company News

In January 2024, Illumina and Janssen Research & Development are collaborating to create a molecular residual disease assay to detect circulating tumor DNA and improve our understanding of disease persistence or recurrence after clinical intervention.

In May 2023, Thermo Fisher Scientific Inc. and Pfizer are partnering to expand access to next-generation sequencing testing for lung and breast cancer patients in over 30 countries across Africa, Latin America, Asia, and the Middle East. This collaboration aims to expedite the analysis of relevant genes for more informed patient therapy decisions.

In April 2023, Agilent Technologies Inc. unveiled a new NGS assay designed to advance precision oncology through comprehensive genomic profiling.

In September 2023, Neuron23, a U.S.-based biotech company, partnered with QIAGEN to create a complementary diagnostic tool for Neuron23's LRRK2 inhibitor, which is used to treat Parkinson's disease. The assay is integrated into an NGS workflow using QIAGEN's capabilities.

In April 2022, Thermo Fisher Scientific launched the Ion Torrent Genexus Dx Integrated Sequencer. This CE-IVD mCE-IVD-marked form provides results within a day, driving growth in the platform product segment.

Product -Market breakup in 3 viewpoints:

1. Instruments

2. Reagents & Consumables

3. Services

Application - Market breakup in 5 viewpoints:

1. Diagnostics

2. Agriculture and Animal Research

3. Drug Discovery

4. Personalized Medicine and Genetic Screening

5. Others

Technology - Market breakup in 5 viewpoints:

1. Sequencing by Synthesis

2. Ion Semiconductor Sequencing

3. Single-Molecule Read Time Sequencing

4. Nanopore Sequencing

5. Others

End-Users -Market breakup in 4 viewpoints:

1. Academic and Clinical Research Centers

2. Pharmaceutical and Biotechnology Companies

3. Hospitals and Clinics

4. Others

All the Key players have been covered from 5 Viewpoints:

1. Overviews

2. Key Person

3. Recent Developments & Strategies

4. Product Portfolio & Product Launch in Last 1 Year

5. Revenue

Company Analysis:

1. Illumina

2. Thermo Fisher Scientific

3. Pacific Biosciences of California

4. QIAGEN N.V

5. Roche

6. Bio-Rad Laboratories, Inc.

7. Takara Bio Inc.

8. Hamilton Company

9. Geneious,

10. BioMerieux SA.

Customization Services available

• Analysis of Market Size and Its Segments
• More Company Profiles (Upto 10 without any additional cost):
• Additional Countries (Other than mentioned Countries):
• Region/Country Specific Reports:
• Market Entry Strategy:
• Region-Specific Market Dynamics:
• Regional Market Share Analysis:
• Trade Analysis:
• Production Insights:
• Others Customized Requests:

For more information contact our analysts.

Need More Assistance?

• Talk to our analysts to get more precious information on the current market trends.
• Include more countries and segments and customize the report based on the final requirement.
• Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
• Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.